Whilst the Phase III CLEOPATRA (NCT00567190) and Phase II EMILIA trials (NCT00829166) demonstrated the efficacy of trastuzumab and trastuzumab emtansine respectively in HER2+ breast cancer, elderly patients remain underrepresented in these type of clinical trials. Thomas Meyskens, MD, PhD, EORTCKU Leuven, Leuven, Belgium, gives an overview of longterm followup data from the Phase II EORTC 75111 trial (NCT01597414) of pertuzumab and trastuzumab with or without cyclophosphamide in elderly patients with HER2+ breast cancer. Addition of cyclophosphamide did not increase toxicity and overall survival as well as progressionfree survival remained superior in the cohort that received cyclophosphamide. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.